Purpose of this Advisory

Moxifloxacin solution is frequently injected at the conclusion of cataract surgery for endophthalmitis prophylaxis. Two different concentrations are commonly available in the United States (U.S.) for intracameral (IC) use: 0.5% [5 mg/mL] and 0.1% [1 mg/mL]. The recommended volume to be injected is different for the two concentrations, and incorrect dosing can increase the risk of toxic anterior segment syndrome (TASS) or endophthalmitis. In addition, the U.S. Food and Drug Administration (FDA) recently published an alert regarding potential adverse events associated with intraocular compounded moxifloxacin.1 This clinical advisory reviews the optimal dosing of IC moxifloxacin based on current evidence.